Clinically significant liver injury, including acute liver failure resulting in/leading to transplant and/or death, has been reported in patients treated with Bruton tyrosine kinase inhibitors, including CENRIFKI in clinical trials. Patients with pre-existing liver disease and patients taking other hepatotoxic drugs, herbal or dietary supplements may be at increased risk for developing liver injury when taking CENRIFKI. Concomitant use of CENRIFKI with other hepatotoxic drugs especially during the first 12 weeks of administration should be undertaken with caution, and alternative options for those drugs should be considered if possible. The use of herbal or dietary supplements with potential hepatotoxicity should be avoided during CENRIFKI treatment.
.png){kind=icon}